Figure 1.
Enrollment of DILI patients and healthy control subjects. CHB, chronic hepatitis B; AIH, autoimmune hepatitis; NAFLD, nonalcoholic fatty liver disease; HHT, hereditary hemorrhagic telangiectasia; MDA, malondialdehyde; GSH-Px, glutathione peroxidase; FGF19, fibroblast growth factor 19. (Created with BioRender.com.).